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ABSTRACT 
Background: Perianal fistula occur in up to 43% of patients with Crohn’s disease. In Crohn’s disease it is important to identify 
the site of inflammation, area involved and based on that the treatment regimen is decided. Perianal abscesses must be drained 
and perianal fistulas must be treated with surgical and medical management. In this case report we would discuss about a 
patient who underwent failure with first line treatment and developed fistula. His symptoms decreased with due course of 
management and was advised for surgical procedure along with medical management. 
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nflammatory bowel disease is an immune mediated 
chronic intestinal condition. Crohn’s disease can affect 
anywhere from mouth to anus. There is an alteration in 
the supraorganism (microbiota, intestinal epithelial cells 
and immune cells) by environmental and genetic factors. 
Chronic diarrhoea, fatigue, weight loss, abdominal pain, 
enterovesical fistulas, enterocutaneous fistulas are the most 
common features. Along with anemia, dyselectrolytemia 
and coagulopathy. Apthoid ulceration and focal crypt 
abscesses with loose aggregation of macrophages are 
appreciated microscopically in patients who have Crohn’s 
disease. 
      It involves ileo-colon, jejunum and may also present as 
perianal disease. Infections like Helicobacter-pylori, 
Cytomegalovirus, and Clostridium difficile are common. 
Patients are treated based on whether they are mild to 
moderate, moderate to severe fistulizing crohn’s disease. 
Mild to moderate are normally managed with budesonide, 
sulfasalazine (colon), predisone, 6MP, Infliximab, 
adalimumab or vedolizumab. Moderate to severe cases are 
managed with 6MP+Inliximab, Ustekinumab, 
Vedolizumab, Glucorticoid i.v. Whereas Fistulizing cases 
are managed with drainage of abscess and antibiotics, 
Total parenteral nutrition, 6MP/ Azathioprine/ 
methotrexate+Infliximab/ adalimumab/ cetrolizumab 
pegol. 
CASE REPORT 
21 years old patient with a background of Crohn’s disease 
came with chief complaint of loose stool and fever since 
one month. Patient was apparently alright one month 
before when he started having stool which was watery in 
consistency and associated with abdominal pain and fever. 
Fever was of mild to moderate grade. He was having 
faecal incontinence since one week. This patient 
previously had perianal involvement of Crohn’s disease, 
for which he underwent fistulotomy few years back. He 
was also known to have thiopurine S- methyltransferase 
activity (TPMT) wild type and was on Infliximab before 
he came with the above complaints. An Inteferon gamma 
release assay test for tuberculosis which was done in April 
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2018 was negative. 
      On admission after clinical examination it was found 
his temperature was 99.2F, BP-110/70mm/Hg, Pulse-108, 
His abdomen was tense. Guarding and rigidity were noted. 
Bowel sound were heard more frequently. All routine 
investigations were done which revealed haemoglobin-
10.4, CRP-45.9, stool routine examination showed occult 
blood, 12-14 pus cells/HPF, fecal calprotectin->3000, 
urine C/S, Stool C/S, Cytomegalo virus IgM and 
Clostridium difficile were negative. He was started on 
empirical antibiotics i.v. piperacillin/ tazobactam and 
i.v.metronidazole. Initially a daily fever spike of 99.2F to 
100.4F was noted. CDAI (Crohn’s diasease activity index) 
was 478. Colonoscopy was performed [Figure 1], it 
revealed deep punched out ulcers intervening mucosa in 
rectum, sigmoid colon, distal colon and ileocaecal 
involvement with narrowing and ulceration of ileocaecal 
valve plus terminal ileal ulcers, large fistula in perianal 
area was seen.  
 
     
Figure 1a: Terminal ileus, Figure 1b: Ileocaecal valve, Figure 1c: Rectal and sigmoidal ulcers (pointed by the arrow),  
  
                 Figure 1d: Rectal ulcers (pointed by arrow)            Figure 1e: Large perianal fistula  
      CECT enterography was done [Figure 2] which 
revealed extensive involvement of colon and distal ileum 
with concentric wall thickening and mural stratification 
suggestive of Crohn’s disease, mesenteric lymph nodes 
were also noted. Gradually his stool consistency changed 
from watery to semisolid, pain in abdomen decreased 
considerably and abdomen became soft. Repeat 
investigation revealed TLC-7200, CRP-31.4, ESR-75. He 
was planned to be started on Adalimumab and undergo 
seton procedure for perianal fistula. He was discharged in 
hemodynamically stable condition. 
DISCUSSION 
Crohn’s disease typically involves small intestine, ileo 
caecal part is involved commonly. Its disease is a relapsing 
systemic inflammatory disease, mainly affecting the 
gastrointestinal tract with extraintestinal manifestations 
and associated immune disorders. It was found that there is 
great variability in the concentrations of calprotectin in 
stool samples collected during a single day. As the levels 
of calprotectin increased with longer time between the 
bowel movements, it seems most appropriate to analyse 
stool from the first bowel movement in the morning. 
Moreover, storage of stool samples at room temperature 
for more than 3 days is not advisable [2].  
Dietary therapy involving partial enteral nutrition 
with an exclusion diet seems to lead to high remission 
rates in early mild-to-moderate luminal Crohn's disease in 
children and young adults [3]. Low vitamin D levels are 
associated with disease activity in CD and increase after 
infliximab treatment [4].
 
Anal fistula plug in patients with 
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Crohn's disease is a safe procedure with reasonable 
success, little morbidity and a low risk of incontinence. 
Ideal surgical treatment for anal fistula should aim to 
eradicate sepsis and promote healing of the tract, whilst 
preserving the sphincters and the mechanism of 
continence. The anal fistula plug, derived from porcine 
small intestinal submucosa, is safe but modestly effective 
in long-term follow-up, with success rates varying from 
24%-88% [1]. 
 
  
Figure 2a, 2b: Images of CECT abdomen
     Studies have shown that higher maintenance infliximab 
trough concentrations are associated with more favourable 
rates of biochemical, endoscopic, or histologic remission 
in Crohn’s disease patients and that infliximab 
concentrations may differ based on the treatment goal [5]. 
The significant role of microorganisms in the pathogenesis 
of inflammatory bowel disease seems apparent, although it 
is complex. Whether it is one pathogenic germ or more 
than one in unison with the gut microbiota as helper, main 
character or observer needs to be elucidated.  In Crohn’s 
disease, we see an inappropriate response of the innate 
and/or adaptive immune system to the intestinal microbiota 
in genetically predisposed individuals. The diagnosis of 
Crohn’s disease is based mainly on patient's history 
and clinical findings and supported by serologic, 
radiologic, endoscopic, and histologic findings. Infliximab 
is not superior to placebo in preventing clinical recurrence 
after Crohn’s disease-related resection. However, 
infliximab does reduce endoscopic recurrence [6,7]. 
  In study of Yarur et al it was found that, the ADA 
level that was best associated with histologic healing was 
7.8 µg/mL, whereas the ADA level that was best 
associated with endoscopic healing was 7.5 µg/mL [8]. 
Detection of Cytomegalovirus genome or antigen in the 
intestine was commonly associated with Inflammatory 
Bowel disease [9]. Our patient was started on Infliximab 
and planned for seaton procedure and called for follow up 
after 1 month. 
CONCLUSION 
Patients are treated based on whether they are mild to 
moderate, moderate to severe fistulizing crohn’s disease. 
Mild to moderate are normally managed with budesonide, 
sulfasalazine, predisone, 6MP, Infliximab, adalimumab or 
vedolizumab. Moderate to severe cases are managed with 
6MP+Inliximab, Ustekinumab, Vedolizumab, Glucorticoid 
i.v. Whereas Fistulizing cases are managed with drainage 
of abscess and antibiotics. Total parenteral nutrition, 6MP/ 
Azathioprine/methotrexate+Infliximab/adalimumab/ 
cetrolizumab pegol. Patients can have various 
complications like fistula, infection. On some cases it is 
essential to rule out tuberculosis. This patient was treated 
accordingly and will be on follow up. 
REFERENCES 
1. Nasseri Y, Cassella L, Berns M, et al. The anal fistula 
plug in Crohn's disease patients with fistula‐ in‐ ano: a 
systematic review. Colorectal Disease. 2016 
Apr;18(4):351-6. 
Guha et al                                                             Management of Relapsing Crohn's Colitis and perianal fistula 
Vol 4| Issue 4| Oct- Dec 2019                                                                                                Eastern J Med Sci 172 
2. Lasson A, Stotzer PO, Öhman L, et al. The intra-
individual variability of faecal calprotectin: a prospective 
study in patients with active ulcerative colitis. Journal of 
Crohn's and Colitis. 2014 Dec 18;9(1):26-32. 
3. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial 
enteral nutrition with a Crohn's disease exclusion diet is 
effective for induction of remission in children and young 
adults with Crohn's disease. Inflammatory bowel diseases. 
2014 Jun 30;20(8):1353-60. 
4. Ham M, Longhi MS, Lahiff C, et al. Vitamin D levels in 
adults with Crohn's disease are responsive to disease 
activity and treatment. Inflammatory bowel diseases. 2014 
Mar 27;20(5):856-60. 
5. Papamichael K, Rakowsky S, Rivera C, et al. Association 
between serum infliximab trough concentrations during 
maintenance therapy and biochemical, endoscopic, and 
histologic remission in Crohn’s disease. Inflammatory 
bowel diseases. 2018 Apr 28;24(10):2266-71. 
6. Laass MW, Roggenbuck D, Conrad K. Diagnosis and 
classification of Crohn's disease. Autoimmunity reviews. 
2014 Apr 1;13(4-5):467-71. 
7. Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces 
endoscopic, but not clinical, recurrence of Crohn’s disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
after ileocolonic resection. Gastroenterology. 2016 Jun 
1;150(7):1568-78. 
8. Yarur AJ, Jain A, Hauenstein SI, et al. Higher 
adalimumab levels are associated with histologic and 
endoscopic remission in patients with Crohn's disease and 
ulcerative colitis. Inflammatory bowel diseases. 2016 Jan 
11;22(2):409-15. 
9. Dimitroulia E, Spanakis N, Konstantinidou AE, et al. 
Frequent detection of cytomegalovirus in the intestine of 
patients with inflammatory bowel disease. Inflammatory 
bowel diseases. 2006 Sep 1;12(9):879-84. 
 
 
 
  
 
 
 
 
 
Funding: None; Conflict of Interest: None Stated. 
How to cite this article:  Guha
 
A, Chaurasia
 
K, Singh
 
HD, Joshi
 
M, Pal
 
BB. Relapsing severe Crohn’s colitis 
and perianal fistula on Infliximab maintenance therapy. 
Eastern J Med Sci. 2019;4(4):169-172. 
DOI:  10.32677/EJMS.2019.v04.i04.006  
